Literature DB >> 22530565

Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.

J Wiegand1, M Kühne, P Pradat, J Mössner, C Trepo, H L Tillmann.   

Abstract

BACKGROUND: The histological pattern of fibrosis in liver cirrhosis varies in different chronic liver diseases, and hepatic decompensation may be differentiated in consequences of fibrosis (i.e. ascites, variceal bleeding) or in lack of function (i.e. jaundice) resulting in aetiology-specific variable morbidity and mortality. AIM: To evaluate patterns of hepatic decompensation in relation to the aetiology of liver cirrhosis.
METHODS: Two different cohorts were retrospectively evaluated between 2002 and 2007. Cohort A was for hypothesis generation and consisted of 220 cirrhotic patients. To confirm the initial observations a second cohort B (n = 217) was analysed. The different patterns of hepatic decompensation evaluated were ascites, jaundice, encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome or hepatocellular carcinoma. Furthermore, we analysed survival in relation to pattern of decompensation in alcoholic vs. non-alcoholic liver disease.
RESULTS: Alcoholics were more frequently hospitalised for ascites (cohort A: 81.4% vs. 65.4%, P = 0.016; cohort B 71.3% vs. 58.5%, P = 0.085). In contrast, non-alcoholics presented with higher rates of hepatocellular carcinoma (cohort A: 23.1% vs. 11.9%, P = 0.046; cohort B 38.6% vs. 22.5%, P = 0.018). There were no significant differences in jaundice, variceal bleeding, hepatorenal syndrome or encephalopathy. Survival was significantly impaired in non-alcoholic cirrhosis once ascites occurred (P = 0.003), whereas ascites did not predict higher mortality in patients with alcoholic cirrhosis.
CONCLUSIONS: Ascites is the leading initial pattern of decompensation in alcoholic cirrhosis whereas hepatocellular carcinoma dominates in non-alcoholics. Non-alcoholics developing ascites show a poor survival.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22530565     DOI: 10.1111/j.1365-2036.2012.05108.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

Review 1.  Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease.

Authors:  Nobuyuki Toshikuni; Mikihiro Tsutsumi; Tomiyasu Arisawa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 2.  Inflammatory status in human hepatic cirrhosis.

Authors:  María Martínez-Esparza; María Tristán-Manzano; Antonio J Ruiz-Alcaraz; Pilar García-Peñarrubia
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

3.  MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy.

Authors:  Valérie Martel-Laferrière; Caitlin Homberger; Kian Bichoupan; Douglas T Dieterich
Journal:  BMC Gastroenterol       Date:  2014-10-17       Impact factor: 3.067

4.  The burden of liver cirrhosis in mortality: Results from the global burden of disease study.

Authors:  Fei Ye; Mimi Zhai; Jianhai Long; Yi Gong; Chutong Ren; Dan Zhang; Xiang Lin; Sushun Liu
Journal:  Front Public Health       Date:  2022-08-11

5.  CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis.

Authors:  Jin Hee Jeong; In Sung Park; Dong Hoon Kim; Seong Chun Kim; Changwoo Kang; Soo Hoon Lee; Tae Yun Kim; Sang Bong Lee
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

6.  The Effect of the First Spontaneous Bacterial Peritonitis Event on the Mortality of Cirrhotic Patients with Ascites: A Nationwide Population-Based Study in Taiwan.

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Yu-Hsi Hsieh; Chih-Chun Tsai; Chih-Wei Tseng; Kuo-Chih Tseng
Journal:  Gut Liver       Date:  2016-09-15       Impact factor: 4.519

7.  A nationwide population-based prospective study of cirrhosis in Iceland.

Authors:  Sigurdur Olafsson; Sigurjon Rögnvaldsson; Ottar M Bergmann; Jon G Jonasson; Ubaldo Benitez Hernandez; Einar S Björnsson
Journal:  JHEP Rep       Date:  2021-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.